Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 21 2025
0mins
Source: Newsfilter
Acquisition Announcement: Paratek Pharmaceuticals has completed the acquisition of Optinose, expanding its portfolio to include the nasal spray XHANCE alongside its antibiotic NUZYRA. The deal was valued at approximately $330 million and aims to enhance Paratek's capabilities in addressing unmet medical needs.
Future Growth Plans: Paratek's CEO emphasized that this acquisition is a strategic step towards becoming a multi-product specialty therapeutics company, with plans to explore further product acquisitions to strengthen their market position.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
